Meningioma epidemiology and demographics

Jump to navigation Jump to search

Meningioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningioma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningioma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningioma epidemiology and demographics

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningioma epidemiology and demographics

CDC on Meningioma epidemiology and demographics

Meningioma epidemiology and demographics in the news

Blogs on Meningioma epidemiology and demographics

Directions to Hospitals Treating Meningioma

Risk calculators and risk factors for Meningioma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Overview

The incidence of meningioma is approximately 7.62 per 100,000 individuals in the United States.[1] The prevalence of meningioma was estimated to be 97.5 cases per 100,000 individuals in the United States.[2] Meningiomas may appear at any age, but are most commonly noticed among patients older than 50 years of age.[3] Females are more commonly affected with meningiomas than males.[2] Meningioma usually affects individuals of the African American race. Caucasian and Latin American individuals are less likely to develop meningioma.[2]

Epidemiology and Demographics

Incidence

  • The incidence of meningiomas is approximately 7.62 per 100,000 individuals in the United States.[1]
  • The advent of modern sophisticated imaging studies tripled the incidence of asymptomatic meningiomas.[3]

Prevalence

  • The prevalence of meningioma was estimated to be 97.5 cases per 100,000 individuals in the United States.[2]
  • Meningioma is the second most common primary brain tumor worldwide.[4]
  • Meningioma accounts for approximately 1 out of 3 primary brain and spinal cord tumors.[5]
  • The prevalence of meningioma was estimated to be around 170,000 individuals in the United States.[2]
  • Benign meningiomas account for approximately 70% of all meningioma cases.[5]
  • Atypical meningiomas account for approximately 15%–25% of all meningioma cases.[5]
  • Anaplastic or malignant meningiomas account for about 1%–3% of all meningioma cases.[5]

Age

  • Meningiomas may appear at any age, but are most commonly noticed among patients older than 50 years of age.[3]
  • Meningiomas are uncommon among patients before the age of 40 and should raise suspicion of neurofibromatosis type 2 (NF2) when found among young patients.[6]

Gender

  • Females are more commonly affected with meningiomas than males.[2]
  • The female to male ratio is approximately 2 to 1.[2]
  • The incidence of meningioma among females is approximately 10.22 per 100,000 individuals in the United States.[1]
  • The incidence of meningioma among males is approximately 4.85 per 100,000 individuals in the United States.[1]
  • The female to male ratio of meningiomas may be inverted among patients who are younger than 15 years of age.[2]

Race

  • Meningioma usually affects individuals of the african american race. Caucasian and latin american individuals are less likely to develop meningioma.[2]

References

  1. 1.0 1.1 1.2 1.3 Dolecek TA, Dressler EV, Thakkar JP, Liu M, Al-Qaisi A, Villano JL (2015). "Epidemiology of meningiomas post-Public Law 107-206: The Benign Brain Tumor Cancer Registries Amendment Act". Cancer. 121 (14): 2400–10. doi:10.1002/cncr.29379. PMID 25872752.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 Wiemels J, Wrensch M, Claus EB (2010). "Epidemiology and etiology of meningioma". J Neurooncol. 99 (3): 307–14. doi:10.1007/s11060-010-0386-3. PMC 2945461. PMID 20821343.
  3. 3.0 3.1 3.2 Meningioma. Wikipedia(2015) https://en.wikipedia.org/wiki/Meningioma#cite_note-pmid7731706-9 Accessed on September, 25th 2015
  4. Chamberlain MC, Barnholtz-Sloan JS (2011). "Medical treatment of recurrent meningiomas". Expert Rev Neurother. 11 (10): 1425–32. doi:10.1586/ern.11.38. PMID 21955199.
  5. 5.0 5.1 5.2 5.3 Meningioma. Canadian Cancer Society http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/meningioma/?region=mb September, 25th 2015
  6. Meningeoma. Radiopaedia(2015)http://radiopaedia.org/articles/meningioma Accessed on September, 25th 2015